TABLE 2.

Univariate analysis for serologic response to fourth vaccine

	Positive	Negative	Total	p	OR	95% CI
Age at vaccination 4			67
≤65 y	11	6	17	Reference
>65 y	26	24	50	.37	0.88	[0.67–1.16]
Gender			67
Male	26	21	47	Reference
Female	11	9	20	.98	1	[0.77–1.3]
Years since diagnosis			67	<.001	0.95	[0.93–0.98]
Past anti‐CD20 Tx			67
No	28	5	33	Reference
Yes	9	25	34	<.001	0.56	[0.46–0.68]
Tx at vaccine 4			66
Untreated	27	7	34	Reference
BTKi	8	14	22	<.001	0.65	[0.51–0.82]
BCL2i	2	8	10	<.001	0.55	[0.4–0.75]
Active Tx at vaccine 4
No	28	7	34	Reference
Yes	9	23	32	<.001	0.6	[0.48–0.73]
Hemoglobin (mg/dL)			67	.72	1.01	[0.96–1.07]
Platelets (K/μL)			67	.028	1.0026	[1.0037–1.0014]
WBC (K/μL)			67	.746	1.05	[0.78–1.42]
ALC			67	.31	1.11	[0.91–1.34]
ANC			67	.74	1.1	[0.62–1.98]
IgG			67
>median	19	14	33	Reference
<median	18	16	34	.7	0.95	[0.75–1.22]
IgA			67
>median	18	15	33	Reference
<median	19	15	34	.9	1.01	[0.8–1.29]
IgM			67
>median	20	13	33	Reference
<median	17	17	34	.4	0.9	[0.71–1.14]
Vaccine 2 seropositivity			53
Negative	19	25	44	Reference
Positive	8	1	9	.011	1.58	[1.12–2.22]
Vaccine 3 seropositivity			67
Negative	1	9	10	Reference
Indeterminate	3	11	14	.51	1.12	[0.8–1.57]
Positive	26	7	33	<.001	1 99	[1.48–2.67]
Pre vaccine 4 seropositivity			67
Negative	4	30	34	Reference
Positive	33	0	33	<.001	2.42	[2.16–2.7]